Gionata Fiorino to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications Gionata Fiorino has written about Tumor Necrosis Factor-alpha.
Connection Strength
0.925
-
The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. Aliment Pharmacol Ther. 2018 11; 48(9):941-950.
Score: 0.354
-
Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile. Curr Med Chem. 2019; 26(2):280-287.
Score: 0.090
-
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Dig Liver Dis. 2019 04; 51(4):510-515.
Score: 0.089
-
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. Inflamm Bowel Dis. 2018 10 12; 24(11):2442-2451.
Score: 0.089
-
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion. 2017; 96(3):166-172.
Score: 0.082
-
Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. Dig Liver Dis. 2017 Aug; 49(8):872-877.
Score: 0.080
-
The safety of biological pharmacotherapy for the treatment of ulcerative colitis. Expert Opin Drug Saf. 2017 Apr; 16(4):437-443.
Score: 0.080
-
Vedolizumab for the treatment of Crohn's disease. Expert Rev Clin Immunol. 2018 03; 14(3):179-189.
Score: 0.021
-
MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. Gastroenterology. 2017 11; 153(5):1363-1377.e6.
Score: 0.020
-
Novel therapeutic targets for inflammatory bowel disease. J Autoimmun. 2017 Dec; 85:103-116.
Score: 0.020